2007
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal Of Medicine 2007, 357: 2109-2122. PMID: 17984165, DOI: 10.1056/nejmoa0706628.Peer-Reviewed Original ResearchConceptsMajor cardiovascular eventsRisk of deathCardiovascular eventsCholesteryl ester transfer proteinLipoprotein cholesterolFirst major cardiovascular eventHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolEffects of torcetrapibHigh cardiovascular riskNonfatal myocardial infarctionDouble-blind studySystolic blood pressureCoronary heart diseaseRisk of mortalityPlasma lipoprotein levelsEster transfer proteinCoronary eventsCardiac eventsCardiovascular riskUnstable anginaBlood pressurePrimary outcomeSerum potassiumLipoprotein levels
2005
W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease
Nissen S, Tardif J, Crowe T, Thuren T, Shear C, Revkin J. W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. Atherosclerosis Plus 2005, 6: 116. DOI: 10.1016/s1567-5688(05)80456-8.Peer-Reviewed Original Research